Non-exclusive pharmaceutical rebate agreements for tocilizumab under an open-house model

Summary

The procurement concerns non-exclusive pharmaceutical rebate agreements for medicines containing the active ingredient tocilizumab (WHO ATC code L04AC07), concluded under an open-house model pursuant to Section 130a(8) of the German Social Code Book V. No purchase volume or minimum order quantity is guaranteed, and the agreements do not grant supply exclusivity. Agreements end no later than 31 July 2028.